Figure 1. . Gadolinium-enhanced T1 sequences magnetic resonance imaging from case 2.

(A) Right temporal anaplastic pleomorphic xanthoastrocytoma with BRAF V600E mutation before, 38 and 94 days after initiating dabrafenib at 150 mg twice a day and trametinib 2 mg daily. Partial treatment response is seen at day 38 of treatment followed by reoccurrence at day 94 of treatment. (B) Diffuse enhancement of the cauda equina before (left) and radiographic improvement (right) 38 days after concurrent treatment with dabrafenib and trametinib. Recurrence in the spine occurred on day 94 (not shown).